Pfizer, AstraZeneca Issue Statements on Merger Talks - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pfizer, AstraZeneca Issue Statements on Merger Talks

In separate statements issued on April 28, Pfizer and AstraZeneca confirmed previous discussions about a possible mergertook place in January 2014.  AstraZeneca declined to engage in further discussion at that time. Pfizer reported that it contacted AstraZeneca on April 26 seeking to renew discussions; however, AstraZeneca again declined to engage in discussions.

AstraZeneca, it its statement, reported that its board concluded that the proposal, reportedly worth $100 billion, “very significantly undervalued” the company and its prospects. The board also said it was committed to executing the strategy announced in March 2013.

In its statement, Pfizer listed a number of benefits of a combined company, including a strong cancer therapy portfolio, greater depth in immune-oncology, cardiovascular medicines, anti-diabetic medicines, as well as enhanced distribution capabilities. Financial analysts have identified tax advantages for Pfizer; if the two companies combine under a UK-holding company, Pfizer would benefit from lower tax rates in Britain.

Pfizer statement

AstraZeneca statement



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here